Table 3.
Cox proportional hazards of features associated with waitlist dropout
| Univariate HR (95% CI) | p-value | Multivariate HR (95% CI) | p-value | |
|---|---|---|---|---|
| AFP pre-listing ≥250 ng/mL | 2.01 (0.86–4.73) | 0.14 | ||
| AFP pre-listing ≥100 ng/mL | 1.78 (0.87–3.64) | 0.14 | 1.84 (0.81–4.16) | 0.14 |
| AFP pre-listing ≥20 ng/mL | 1.02 (0.58–1.78) | 0.95 | ||
| AFP-L3 pre-listing ≥35% | 3.02 (1.53–5.97) | 0.005 | 2.25 (1.04–4.88) | 0.04 |
| AFP-L3 pre-listing ≥15% | 1.91 (1.09–3.34) | 0.03 | ||
| DCP pre-listing ≥7.5 ng/mL | 2.51 (1.38–4.56) | 0.005 | 2.20 (1.15–4.20) | 0.02 |
| Age | 0.99 (0.95–1.03) | 0.70 | ||
| Gender | 0.46 | |||
| Men | 1.23 (0.70–2.18) | |||
| Women | 1 | |||
| Race | 0.32 | |||
| White | 1 | |||
| Asian/Pacific Islander | 0.54 (0.23–1.24) | |||
| African American | 1.30 (0.45–3.75) | |||
| Hispanic | 1.26 (0.70–2.27) | |||
| Other | 0.91 (0.39–2.13) | |||
| Etiology | 0.64 | |||
| HCV | 1 | |||
| HBV | 0.71 (0.33–1.52) | |||
| Alcohol | 0.56 (0.17–1.82) | |||
| NASH | 0.92 (0.46–1.84) | |||
| Other | 0.50 (0.12–2.06) | |||
| Number of HCC lesions at listing | 0.92 (0.63–1.34) | 0.65 | ||
| Size of largest tumor at listing | 1.10 (0.92–1.32) | 0.32 | ||
| Total tumor diameter at listing | 1.03 (0.91–1.15) | 0.66 | ||
| Tumor stage beyond Milan criteria | 1.82 (1.03–3.22) | 0.05 | 1.62 (0.88–2.97) | 0.12 |
| Number of local regional therapy treatments | 1.07 (0.94–1.22) | 0.35 | ||
| Time to listing after diagnosis >1 year | 2.41 (1.42–4.08) | 0.002 | 2.70 (1.57–4.67) | <0.001 |
| MELD-Na at listing | 1.10 (1.05–1.15) | <0.001 | 1.08 (1.02–1.16) | 0.02 |
| MELD-Na ≥12 at listing | 2.39 (1.43–4.00) | 0.001 | ||
| Child-Pugh Score at listing | 1.28 (1.14–1.44) | 0.002 | 1.11 (0.94–1.31) | 0.23 |
| Neutrophil to lymphocyte ratio at listing | 1.08 (1.02–1.14) | 0.05 | - |